Written by:
Dr. Sophie Reynolds

Dr. Sophie Reynolds is a board-certified medical doctor specializing in internal medicine. With over a decade of experience in patient care and medical writing

Osimert 80 mg Tablet

Brand Name:   Osimert
Molecule:   Osimertinib
Strength:   80 mg
Quantity:   30 Tablets
Form:   Tablet
Packaging Type:   Bottle
Manufacturer/Marketed By:   Everest Pharma
Country of Origin:   Bangladesh

Description

Osimert 80 mg is a prescription oral tablet that contains osimertinib, a third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) developed specifically for patients with non-small cell lung cancer (NSCLC) that carries specific EGFR gene mutations. These mutations, including exon 19 deletions, exon 21 L858R substitutions, and T790M resistance mutations, can cause cancer cells to grow and spread rapidly.  Osimert 80 mg works by selectively binding to these mutant EGFR proteins and blocking their activity, which can help stop or slow the progression of the disease. Unlike earlier EGFR inhibitors, Osimert Osimertinib 80 mg Tablet is designed to cross the blood-brain barrier, making it effective even in patients with brain metastases. It is commonly used in early stages as adjuvant therapy post-surgery, a first-line treatment in metastatic disease, or after other EGFR-TKI therapies have fa

Benefits

Key clinical benefits of Osimert 80 mg Tablet include:

  • Targets specific EGFR gene mutations driving cancer growth

  • Designed for precision-based lung cancer treatment

  • Demonstrated activity in metastatic disease, including brain metastases

  • Oral once-daily dosing for convenience

  • May delay disease progression in eligible patients

Treatment outcomes vary based on individual clinical factors and tumor characteristics.

Indications and Usage

Osimert 80 mg Tablet (Osimertinib 80mg) is indicated for:

  • Treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC)

  • First-line treatment of advanced or metastatic EGFR-mutated NSCLC

  • Patients with tumors that have specific EGFR mutations such as exon 19 deletions or exon 21 L858R substitution

  • Certain patients with T790M resistance mutation (as guided by clinical evaluation)

  • Adjuvant treatment after tumor resection in selected early-stage cases (as per oncologist’s recommendation)

Genetic testing for EGFR mutation is required before starting treatment.

How it Works

Osimertinib 80mg works by blocking the epidermal growth factor receptor (EGFR), a protein found on the surface of some cancer cells.

In EGFR-mutated lung cancer, abnormal activation of this receptor causes uncontrolled cell growth. Osimert 80 mg Tablet binds to and inhibits the mutated EGFR protein, preventing it from sending growth signals to cancer cells.

By blocking this pathway:

  • Tumor cell growth slows

  • Cancer progression may be controlled

  • Spread to other organs may be reduced

Osimertinib is considered a third-generation EGFR inhibitor and is specifically designed to target certain resistance mutations while sparing normal cells more selectively than earlier treatments.

Dosage & Administration

  • Recommended dose: 80 mg once daily

  • Route: Oral (by mouth)

  • Form: Tablet

Osimert 80 mg Tablet should be swallowed whole with water. It may be taken with or without food.

If a dose is missed and it is less than 12 hours before the next dose, skip the missed dose. Do not double the dose.

The exact duration and dose adjustments must be determined by your oncologist based on treatment response, side effects, and overall health.

Side Effects

Like all anti-cancer medicines, Osimertinib 80mg may cause side effects.

Common Side Effects

  • Diarrhea

  • Skin rash or dryness

  • Nail changes

  • Fatigue

  • Mouth sores

  • Decreased appetite

Serious Side Effects

  • Interstitial lung disease (lung inflammation)

  • Heart rhythm changes (QT prolongation)

  • Decreased heart function

  • Severe skin reactions

  • Eye disorders

Immediate medical attention is required if you experience shortness of breath, chest pain, severe rash, or persistent cough.

Regular monitoring, including ECG and blood tests, may be recommended during treatment.

Warning and Precaution

Before starting Osimert 80 mg Tablet, discuss the following with your doctor:

Lung Conditions

Report any history of lung disease. Osimertinib may rarely cause serious lung inflammation.

Heart Monitoring

Patients with heart rhythm disorders or electrolyte imbalance require close monitoring.

Pregnancy and Breastfeeding

  • May cause harm to an unborn baby

  • Effective contraception is required during treatment and for a recommended period after completion

  • Breastfeeding is not advised during therapy

Drug Interactions

Osimertinib may interact with:

  • Strong CYP3A4 inducers

  • Certain antifungal and antibiotic medicines

  • Herbal supplements

Always inform your oncologist about all medicines and supplements you are taking.

FAQ

What kind of drug is Osimert 80 mg?+
Osimert 80 mg (Osimertinib) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It is classified as a targeted cancer therapy specifically designed to treat certain types of non-small cell lung cancer with EGFR mutations.
Is Osimert a form of chemotherapy?+
No, Osimert is not chemotherapy. It is a targeted therapy, which works by selectively inhibiting cancer-driving mutations in EGFR genes. Unlike chemotherapy, which affects both healthy and cancerous cells, Osimert targets specific cancer cells.
What is the use of Osimert 80 mg?+
Osimert 80 mg is used to treat adults with non-small cell lung cancer (NSCLC) that is EGFR mutation-positive, especially the T790M mutation. It may be prescribed as a first-line treatment or after progression on earlier EGFR therapies.
How does Osimert 80 mg work?+
Osimertinib works by binding to mutated EGFR receptors on cancer cells and blocking the signals that promote cancer cell growth and survival. This inhibition helps slow or stop the progression of the cancer.
Is Osimert a targeted therapy?+
Yes, Osimert is a targeted therapy. It specifically targets and inhibits mutated forms of the EGFR gene in non-small cell lung cancer cells.
How effective is Osimert 80 mg in treating cancer?+
Clinical trials show that Osimert 80 mg improves progression-free and overall survival in patients with EGFR-mutant NSCLC. It significantly delays cancer progression compared to older EGFR inhibitors, with median overall survival reaching up to 38.6 months.
Who Manufactured Osimert Osimertinib 80 mg Tablet?+
Osimert Osimertinib 80 mg manufactured by Everest Pharmaceuticals.
What is the cost of Osimert 80 mg?+
In the Global, the price of Osimert 80 mg (Generic Tagrisso – Osimertinib) typically ranges from ₱16,000 to ₱22,000 for a pack of 30 tablets.
Does Osimert 80 mg cause hair loss?+
Hair loss is not a common side effect of Osimert. Compared to chemotherapy, Osimertinib has a much lower risk of causing hair loss. However, individual reactions may vary.
How long does Osimert 80 mg work in the body?+
Osimert has a long half-life of approximately 48 hours. This allows it to maintain effective levels in the body with once-daily dosing, continuously inhibiting EGFR mutations.
How long does it take for Osimert 80 mg to start working?+
Tumor response to Osimert can often be observed within 6 to 12 weeks after starting treatment. However, individual response times may vary.
Can Osimert 80 mg be used during pregnancy or breastfeeding?+
Osimert  80 mg should not be used during pregnancy due to the risk of fetal harm. Breastfeeding is also not recommended while taking this medication, as it’s unknown if the drug passes into breast milk.
Does Osimert 80 mg interact with food or drinks?+
There are no significant known interactions between Osimert and foods or beverages. However, alcohol use should be discussed with your healthcare provider.
Does Osimert 80 mg interact with other medications?+
Yes, Osimertinib may interact with other medications, especially drugs that affect liver enzymes (CYP3A). Always inform your doctor about all prescription, over-the-counter, and herbal supplements you’re taking.
What should I do if I take too much Osimert 80 mg?+
In case of overdose, seek emergency medical attention immediately. You can contact a local emergency number or a poison control center.
What should I do if I miss a dose of Osimert 80 mg?+
If you miss a dose, take it as soon as you remember. If it’s close to your next dose, skip the missed dose and continue your regular schedule. Do not take a double dose.
Does Osimert 80 mg cause bleeding?+
Bleeding is a rare but possible side effect. Some patients may experience nosebleeds or bruising. Report any unusual bleeding to your doctor immediately.
Can Osimert 80 mg cause infertility?+
Osimert may affect fertility in both men and women. Discuss fertility preservation options with your doctor before starting treatment.
What is the life expectancy of someone taking Osimert?+
In clinical studies, patients on Osimert had a median overall survival of approximately 38.6 months, significantly longer than earlier treatments. Individual prognosis depends on several factors, including cancer stage and overall health.
What foods should you avoid when taking Osimert?+
There are no specific foods that need to be avoided while taking Osimertinib. However, due to potential enzyme interactions, maintaining a balanced diet and avoiding grapefruit or grapefruit juice (if advised) is recommended.
Does Osimert shrink tumors?+
Yes, Osimert has been shown to shrink tumors in many patients with EGFR mutation-positive NSCLC. It often results in partial or complete tumor response, especially in early stages of treatment.

Related Products

Related Posts:

Ruxolitinib Tablets Receive FDA Approval for Hematologic Malignancies

The U.S. Food and Drug Administration (FDA) has approved Ruxolitinib tablets for the treatment of certain hematologic malignancies, marking another

READ MORE »
Tovorafenib Approved in Europe for Children with BRAF-Altered Low-Grade Glioma

n Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 14, 2026.n n This marks an important

READ MORE »
FDA Fast-Tracks Plixorafenib for BRAF V600E–Mutated Brain Tumors

n Medical Review: This article was reviewed by Dr. Sophie Reynolds on April 14, 2026.n n Brain tumors, especially high-grade

READ MORE »
0 reviews
0
0
0
0
0

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.